SCHEMBL24490266

SCHEMBL24490266

Cc1cc2c(s1)CN(C(=O)CC#N)C[C@H]2c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 10/20 0.42
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
SLC6A2 P23975 5/20 0.34
SLC6A4 P31645 5/20 0.34
SLC6A3 Q01959 5/20 0.34
ESR1 P03372 1/20 0.34
ESR2 Q92731 1/20 0.34
LMNA P02545 2/20 0.34
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
PMP22 Q01453 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22460961 1.00 KIF11 (0.42) KIF11KDM4EMEN1ALDH1A1MAPT
SCHEMBL24490136 0.79 KIF11 (0.42) KIF11MEN1KMT2ASLC6A2SLC6A4
SCHEMBL24490132 0.79 KIF11 (0.42) KIF11MEN1KMT2ASLC6A2SLC6A4
SCHEMBL24490010 0.76 RAB9A (0.47) KIF11KDM4EMEN1ALDH1A1MAPT
SCHEMBL24490011 0.76 RAB9A (0.47) KIF11KDM4EMEN1ALDH1A1MAPT
SCHEMBL11219861 0.76 SLC6A2 (0.56) KIF11SLC6A2SLC6A4SLC6A3LMNA
SCHEMBL24490198 0.72 KIF11 (0.40) KIF11KDM4EMAPTSLC6A2SLC6A4
SCHEMBL24490200 0.70 KIF11 (0.37) KIF11KDM4EMAPTSLC6A2SLC6A4
SCHEMBL24489992 0.68 ACHE (0.41) KIF11MEN1ALDH1A1MAPTKMT2A
SCHEMBL24489991 0.68 ACHE (0.41) KIF11MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220177488-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF CIT THERAPEUTICS LLC 2022-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220177488-A1 SUMO INHIBITOR COMPOUNDS AND USES THEREOF SUMO1, SUMO2, SUMO3 KIF11 3058/4885KDM4E 876/4885MEN1 1693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.